These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28244816)

  • 21. Translational research insights from completed HIV vaccine efficacy trials.
    Tieu HV; Rolland M; Hammer SM; Sobieszczyk ME
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2():S150-4. PubMed ID: 23764628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Status and current strategies of HIV vaccine development].
    Wild J; Wagner R
    Internist (Berl); 2003 Jun; 44(6):711-8. PubMed ID: 14567107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AIDS vaccine: efficacy, safety and ethics.
    Veljkovic V; Veljkovic N; Glisic S; Ho MW
    Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Advances in the Immunogenic Design of HIV-1 Vaccine].
    Zhang X; Wang T; Yu X
    Bing Du Xue Bao; 2016 Jan; 32(1):88-92. PubMed ID: 27295889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.
    Hassapis KA; Stylianou DC; Kostrikis LG
    Viruses; 2014 Dec; 6(12):5047-76. PubMed ID: 25525909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current strategies and limitations of HIV vaccines.
    Kawalekar OU; Shedlock DJ; Weiner DB
    Curr Opin Investig Drugs; 2010 Feb; 11(2):192-202. PubMed ID: 20112169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
    Koff WC
    Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.
    Longini IM; Datta S; Halloran ME
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(5):440-7. PubMed ID: 8970471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential contribution of gut microbiota and systemic inflammation on HIV vaccine effectiveness and vaccine design.
    Routy JP; Mehraj V
    AIDS Res Ther; 2017 Sep; 14(1):48. PubMed ID: 28893288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AIDS vaccine development: the long and winding road.
    Garber DA; Feinberg MB
    AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the HIV-1deltakURNe vaccine strain hold the key to curbing HIV infection? An interview with Ronald Desrosiers, PhD.
    Desrosiers R
    J Int Assoc Physicians AIDS Care; 1998 Mar; 4(3):45-6. PubMed ID: 11365180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects for a Globally Effective HIV-1 Vaccine.
    Excler JL; Robb ML; Kim JH
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress and obstacles in the development of an AIDS vaccine.
    Letvin NL
    Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
    Tomaras GD; Plotkin SA
    Immunol Rev; 2017 Jan; 275(1):245-261. PubMed ID: 28133811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV vaccines: an attainable goal?
    Reynell L; Trkola A
    Swiss Med Wkly; 2012; 142():w13535. PubMed ID: 22389197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can HIV infection be prevented with a vaccine?
    Joy AK; Dale CJ; Kent SJ
    Drugs R D; 1999 Jun; 1(6):431-40. PubMed ID: 10566076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors.
    Koup RA; Graham BS; Douek DC
    Nat Rev Immunol; 2011 Jan; 11(1):65-70. PubMed ID: 21164527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV vaccine development at the turn of the 21st century.
    Girard MP; Plotkin SA
    Curr Opin HIV AIDS; 2012 Jan; 7(1):4-9. PubMed ID: 22156840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.